However, it is noteworthy that CDK9 mutations or amplifications rarely occur in cancer patients, especially in NSCLC 11, raising the concerns about the specificity of CDK9 inhibitors and their potential impact on normal cells. Here, CDK9 is linked to non-small cell lung carcinoma.